TNF and COVID-19: The DPP4 inhibitor also improves bronchoalveolar lavage IL-6 and TNF-α levels in LPS-induced mice and attenuates lung injury (69), meaning direct stimulation of anti-inflammatory activity in the lungs may help ameliorate lung damage from COVID-19.